NL-OMON39829尚未招募3 期
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research Group - H11 / EORTC 20101-23101
European Organisation for Research in Treatment of Cancer (EORTC)0 个研究点目标入组 190 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Previously untreated, histologically proven classical Hodgkin lymphoma
- •* Clinical stages III/IV (Ann Arbor, see Appendix F)
- •* Age 18-60
- •* WHO performance 0-2 (see Appendix C)
- •* FDG-PET/CT scan prospectively planned after one cycle of chemotherapy in all patients
- •* Adequate organ function:;* Heart:
- •New York Heart Association (NYHA) functional classification <= II (EF >= 50% or FS >= 25%)
- •No symptomatic coronary heart disease (stable angina pectoris is allowed),
- •No severe uncontrolled hypertension.;* Liver: Total Bilirubin <= 2 x UNL, alanine aminotransferase (ALT, SGPT) <= 3 x UNL, aspartate aminotransferase (AST, SGOT) <= 3 x UNL (exception: elevated values due to HL liver involvement).;* Kidney: creatinine clearance >= 60 ml/min (measured or calculated according to the method of Cockcroft), uric acid, calcium (all <UNL).;* Hematological: Hemoglobin >= 10 g/dl, Leukocyte concentration >= 3.0 x 109/L absolute neutrophil count >= 1.5 x 109/L, platelets >= 75 x 109 /L. (exception: reduced values related to HL (e.g. BM infiltration, splenomegaly));Patients with a buffer range from the normal values of +/- 10% for hematology and +/- 10% for biochemistry are acceptable.;* Patients of childbearing/reproductive potential should use adequate birth control measures during the whole duration of study treatment.;* Female subjects of childbearing potential (defined as any female subject unless she meets at least one of the following criteria: Age >=50 years and naturally amenorrheic for >= 1 year {amenorrhea following cancer therapy does not rule out childbearing potential}, premature ovarian failure confirmed by a specialist gynecologist, previous bilateral salpingo-oophorectomy or hysterectomy, XY genotype, Turner syndrome or uterine agenesis.) must:;* Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml not more than 3 days before the start of study medication. This requirement also applies to women of childbearing potential who practice complete and continued abstinence;* Male subjects must:;* Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy if their partner is of childbearing potential and has no contraception.;* Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.;* Written informed consent according to ICH/EU Good Clinical Practice, and national/local regulations
排除标准
- •No pregnancy or breast feeding
- •* No specific contraindications to BEACOPPesc therapy, so therefore:
- •* poorly controlled diabetes mellitus
- •* known HIV infection
- •* chronic active hepatitis B and/or hepatitis C
- •* concomitant or previous malignancies with the exception of basal cell skin tumors, adequately treated carcinoma in situ of the cervix and any cancer that has been in complete remission for > 5 years
- •* No psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial.
研究者
相似试验
进行中（未招募）
不适用
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.Advanced stage Hodgkin's lymphomaMedDRA version: 15.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-005473-22-DKEORTC570
进行中（未招募）
1 期
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.Advanced stage Hodgkin's lymphomaMedDRA version: 14.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-005473-22-BEEORTC570
进行中（未招募）
1 期
Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II studyAdvanced stage Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10020206Term: Hodgkin's diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10020243Term: Hodgkin's disease NECSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000498-35-PLEuropean Organisation for Research and Treatment of Cancer (EORTC)150
进行中（未招募）
1 期
Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II studyAdvanced stage Hodgkin LymphomaMedDRA version: 20.1 Level: LLT Classification code 10080208 Term: Classical Hodgkin lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10020206 Term: Hodgkin's disease System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10020243 Term: Hodgkin's disease NEC System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0 Level: HLGT Classification code 10025319 Term: Lymphomas Hodgkin's disease System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0 Level: SOC Classification code 10005329 Term: Blood and lymphatic system disorders System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000498-35-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)150
进行中（未招募）
1 期
Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II studyEUCTR2017-000498-35-DKEuropean Organisation for Research and Treatment of Cancer (EORTC)150